TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)

Category Primary study
ConferenceEHA2023 Hybrid Congress
Year 2023
This article has no abstract
Epistemonikos ID: 8549689dfea3219cb691eac019e676a7801ca1e8
First added on: Apr 25, 2026